- What is Tisch MSRCNY?
- Our Research
- Stem Cell Trial
- Get Involved
This week eight of Tisch MSRCNY’s researchers arrived in Washington, D.C. to attend the 67th American Academy of Neurology Annual Meeting. Eight of the Center’s Abstracts will be presented at the meeting. Dr. Sadiq was also informed on Monday that the preliminary results from our FDA-approved Phase 1 clinical stem cell trial for patients with MS were selected as a presentation during the Multiple Sclerosis Highlights in the Field session on Wednesday, April 22nd.
Tuesday morning, April 21st, researchers Marwan Alahiri, Ying Liu, Bianca Ulloa, and Dr. Sadiq presented the poster "The Protection of A2aR on BBB Permeability from Th1 Cytokines in MS" during Poster Session II, MS and CNS Inflammatory Diseases: In Vitro Studies, Experimental, and Animal Models, at the 67th AAN Annual Meeting.
Wednesday afternoon, April 22nd, Tisch MSRCNY researchers presented a total of six additional posters, including:
“Myelin Oligodendrocyte Glycoprotein is the Primary Myelin Protein Target of CSF B-cell Antibodies in MS,” Authored by Pak Ho Au, Christopher Sears, Jerry Lin, Saud Sadiq
“Metabolite Profiling of Cerebrospinal Fluid Derived from MS Patients,” Authored by Danielle Blemur, Fozia Mir, Saud Sadiq
“Transglutaminase 6 is a potential biomarker of disease activity and astrocytic proliferation in MS,” Authored by Daniel Gratch, Benjamin Pagano, Kelsey McDermott, Massimiliano Cristofanilli, Saud Sadiq
“Cerebrospinal Fluid Haptoglobin (Hp) Levels are elevated in MS patients with progressive disease,” Authored by Bianca Ulloa, Marwan Alahiri, Ying Liu, Saud Sadiq
“Fetuin-A Correlates with Cortical Demyelination and is a CSF Biomarker of Disease Activity in Progressive MS,” Authored by Mark Landy, Violaine Harris, Ying Liu, Saud Sadiq
“Fetuin-A, a CSF Biomarker of MS Disease Activity, is Upregulated at the Blood Brain Barrier,” Authored by Ruth-Anne Langan, Violaine Harris, Mark Landy, Saud Sadiq
Stay tuned over the next several weeks for additional details about each presentation.